0000950170-24-040478.txt : 20240402
0000950170-24-040478.hdr.sgml : 20240402
20240402181042
ACCESSION NUMBER: 0000950170-24-040478
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240325
FILED AS OF DATE: 20240402
DATE AS OF CHANGE: 20240402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Garner Charles
CENTRAL INDEX KEY: 0001602444
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38130
FILM NUMBER: 24816084
MAIL ADDRESS:
STREET 1: 490 LAPP ROAD
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aileron Therapeutics, Inc.
CENTRAL INDEX KEY: 0001420565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 134196017
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12407 N. MOPAC EXPY.
STREET 2: SUITE 250 #390
CITY: AUSTIN
STATE: TX
ZIP: 78758
BUSINESS PHONE: 7378021989
MAIL ADDRESS:
STREET 1: 12407 N. MOPAC EXPY.
STREET 2: SUITE 250 #390
CITY: AUSTIN
STATE: TX
ZIP: 78758
FORMER COMPANY:
FORMER CONFORMED NAME: AILERON THERAPEUTICS INC
DATE OF NAME CHANGE: 20071207
3
1
ownership.xml
3
X0206
3
2024-03-25
0
0001420565
Aileron Therapeutics, Inc.
ALRN
0001602444
Garner Charles
C/O AILERON THERAPEUTICS, INC.
12407 N. MOPAC EXPY, SUITE 250 #390
AUSTIN
TX
78758
false
true
false
false
Senior Vice President, Finance
Stock Option (right to buy)
1.17
2030-03-31
Common Stock
349750
D
Stock Option (right to buy)
2.34
2033-02-09
Common Stock
25597
D
On October 31, 2023, the Issuer completed its merger with Lung Therapeutics, Inc. (the "Merger") in accordance with the terms of the Agreement and Plan of Merger, dated October 31, 2023. In connection with the Merger, the Issuer assumed the Reporting Person's option to purchase 2,049,557 shares of Lung Therapeutics, Inc. common stock originally granted on April 1, 2020, which option was converted into an option to purchase 349,750 shares of Issuer common stock. The shares underlying the options are fully vested.
In connection with the Merger, the Issuer assumed the Reporting Person's option to purchase 150,000 shares of Lung Therapeutics, Inc. common stock originally granted on February 10, 2023, which option was converted into an option to purchase 25,597 shares of Issuer common stock. 25% of the shares underlying the option vested on the first anniversary of the grant date, and, thereafter, the remaining 75% of such shares vest in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service with the Issuer on each applicable vesting date.
/s/ Charles T. Garner
2024-04-02